Follicular lymphoma

European Commission
#AbbVie #European Commission #Follicular lymphoma #Genmab

EC grants marketing authorisation to lymphoma therapy 

The European Commission (EC) has granted marketing authorisation for Tepkinly (epcoritamab) in combination with lenalidomide and rituximab (R2) for the treatment of relapsed or refractory follicular lymphoma.  The combination regimen, developed by AbbVie and Genmab for the treatment of adult patients, is the first and only bispecific-based therapy approved in Europe for the… Read More

#News #Regulatory

#ABPI #Bispecific Antibodies #Clinical trial #Follicular lymphoma #HIV #National Institute for Health and Care Excellence (NICE) #Novo Nordisk #Nuclear medicine #Prostate cancer #UK #ViiV Healthcare

DDW Highlights: 3 March 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, more effective treatments were found for both HIV and chronic wounds. Elsewhere, €40,000… Read More

#Podcasts

#ABPI #Bispecific Antibodies #Clinical trial #Follicular lymphoma #GLP-1 #HIV #National Institute for Health and Care Excellence (NICE) #Novo Nordisk #Nuclear medicine #Obesity #Prostate cancer #UK #ViiV Healthcare #Weight loss

This week in Drug Discovery (23 – 27 February) 

News round-up for 23 – 27 February by Bruno Quinney, Content Team at DDW.  This week in drug discovery, more effective treatments have been found for both HIV and chronic wounds. Elsewhere, €40,000 is up for grabs in prostate cancer research.  The top stories:   … Read More

#News

Non-Hodgkins lymphoma
#Bispecific Antibodies #Follicular lymphoma #National Institute for Health and Care Excellence (NICE)

NICE recommends first bispecific antibody to treat lymphoma 

The National Institute for Health and Care Excellence (NICE) has recommended the first bispecific antibody for the treatment of follicular lymphoma (FL).  Tepkinly (epcoritamab), developed by biopharmaceutical company AbbVie, has been recommended to the NHS as an option to treat adult patients with FL whose cancer has returned or who have… Read More

#News #Regulatory

Diffuse large B-cell lymphoma
#Clinical trial #EMA #Follicular lymphoma

EMA issues positive CHMP opinion on Minjuvi 

The European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Minjuvi (tafasitamab) for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL).  The positive opinion was issued by the EMA’s Committee for Medicinal Products for Human Use (CHMP). The opinion is based on data from… Read More

#News #Regulatory

Monoclonal antibody
#AbbVie #European Commission #Follicular lymphoma #Genmab #Lymphoma #Oncology

Second lymphoma indication approval for Tepkinly in Europe

AbbVie and Genmab’s Tepkinly (epcoritamab) has been granted conditional marketing authorisation by the European Commission (EC) as a monotherapy for relapsed or refractory (R/R) follicular lymphoma (FL) after two or more lines of prior therapy. The approval makes Tepkinly the first subcutaneous T-cell engaging bispecific antibody approved to treat both… Read More

#News #Regulatory

Bispecific antibodies
#AbbVie #ASCO #Bispecific Antibodies #Follicular lymphoma #Genmab #Haematology #Oncology

95% response to bispecific antibody in follicular lymphoma

Previously untreated follicular lymphoma (FL) patients who received epcoritamab with rituximab-lenalidomide (R2) had a 95% overall response rate (ORR), according to preliminary trial data. The results of two ongoing Phase I/II clinical trials evaluating cancer immunotherapy epcoritamab, a T-cell engaging bispecific antibody, were shared at… Read More

#Cancer Research #News #Trending News

Follicular lymphoma
#AbbVie #Bispecific Antibodies #Clinical trials #Follicular lymphoma #Genmab

New data for relapsed/refractory follicular lymphoma treatment 

Genmab and AbbVie have announced updated data presented at ASH from the companies’ ongoing Phase I/II EPCORE NHL-1 clinical trial investigating epcoritamab (DuoBody CD3xCD20).   Epcoritamab is a T-cell engaging bispecific antibody administered subcutaneously in 128 adult patients with relapsed, progressive or refractory CD20+ mature B-cell non-Hodgkin’s lymphoma… Read More

#News